despit
avail
effect
prophylact
vaccin
lead
steril
immun
hepat
b
viru
hbv
respons
chronic
liver
diseas
million
individu
potenti
lead
cirrhosi
hepatocellular
carcinoma
antivir
drug
abl
complet
suppress
viru
replic
inde
avail
larg
unabl
erad
viru
sever
altern
new
treatment
approach
current
develop
none
far
captur
interest
clinician
possibl
clinic
develop
constant
featur
chronic
hbv
infect
tcell
exhaust
result
persist
exposur
high
antigen
concentr
shown
high
express
program
cell
death
protein
hbvspecif
cell
one
way
tackl
problem
develop
hbvspecif
neutral
antibodi
would
clear
excess
envelop
protein
circul
allow
nucleo
ide
analog
antivir
drug
preclin
earli
clinic
develop
take
advantag
reconstitut
adapt
immun
sever
fulli
human
monoclon
antibodi
mab
develop
hbvvaccin
subject
convalesc
acut
hepat
b
show
differ
properti
specif
envisag
neutral
mab
may
use
adjuv
treatment
reduc
viral
protein
load
thu
rescu
adapt
immun
effort
optim
effect
antivir
drug
hepat
b
viru
hbv
respons
acut
chronic
hepat
potenti
lead
cirrhosi
hepatocellular
carcinoma
review
hepat
b
effect
prevent
prophylact
vaccin
wherea
antivir
drug
virtual
unabl
erad
viru
chronic
infect
individu
despit
effici
suppress
hbv
dna
replic
adapt
immun
play
major
role
provid
longterm
control
infect
howev
low
frequenc
circul
hbvspecif
cell
chronic
infect
contribut
inabl
clear
viru
inde
hbv
may
settl
life
occult
form
nuclei
hepatocyt
minichromosom
coval
close
circular
dna
cccdna
despit
appar
recoveri
potenti
reactiv
case
immun
suppress
persist
cccdna
hepatocyt
main
hurdl
erad
hbv
infect
problem
compound
rapid
declin
tcell
bcell
respons
result
exhaust
induc
product
larg
amount
excess
hbv
envelop
protein
larg
result
integr
hbv
despit
avail
effect
prophylact
vaccin
lead
steril
immun
hepat
b
viru
hbv
respons
chronic
liver
diseas
million
individu
potenti
lead
cirrhosi
hepatocellular
carcinoma
antivir
drug
abl
complet
suppress
viru
replic
inde
avail
larg
unabl
erad
viru
sever
altern
new
treatment
approach
current
develop
none
far
captur
interest
clinician
possibl
clinic
develop
constant
featur
chronic
hbv
infect
tcell
exhaust
result
persist
exposur
high
antigen
concentr
shown
high
express
program
cell
death
protein
hbvspecif
cell
one
way
tackl
problem
develop
hbvspecif
neutral
antibodi
would
clear
excess
envelop
protein
circul
allow
nucleo
ide
analog
antivir
drug
preclin
earli
clinic
develop
take
advantag
reconstitut
adapt
immun
sever
fulli
human
monoclon
antibodi
mab
develop
hbvvaccin
subject
convalesc
acut
hepat
b
show
differ
properti
specif
envisag
neutral
mab
may
use
adjuv
treatment
reduc
viral
protein
load
thu
rescu
adapt
immun
effort
optim
effect
antivir
drug
keyword
human
monoclon
antibodi
hbvhepat
b
viru
b
cell
immun
system
adapt
immun
hepat
b
viru
hbv
respons
acut
chronic
hepat
potenti
lead
cirrhosi
hepatocellular
carcinoma
review
hepat
b
effect
prevent
prophylact
vaccin
wherea
antivir
drug
virtual
unabl
erad
viru
chronic
infect
individu
despit
effici
suppress
hbv
dna
replic
adapt
immun
play
major
role
provid
longterm
control
infect
howev
low
frequenc
circul
hbvspecif
cell
chronic
infect
contribut
inabl
clear
viru
inde
hbv
may
settl
life
occult
form
nuclei
hepatocyt
minichromosom
coval
close
circular
dna
cccdna
despit
appar
recoveri
potenti
reactiv
case
immun
suppress
persist
cccdna
hepatocyt
main
hurdl
erad
hbv
infect
problem
compound
rapid
declin
tcell
bcell
respons
result
exhaust
induc
product
larg
amount
excess
hbv
envelop
protein
larg
result
integr
hbv
dna
sequenc
host
genom
particularli
hbeagneg
chronic
hbv
infect
review
note
evid
increas
level
hbsag
may
contribut
cell
dysfunct
hbsag
induc
disrupt
interferonalpha
product
circul
plasmacytoid
dendrit
cell
moreov
hbvspecif
cell
mainli
concentr
intrahepat
compart
togeth
larg
number
hbv
nonspecif
cell
may
contribut
maintain
liver
inflamm
via
antigenindepend
bystand
activ
exhaust
caus
persist
exposur
high
antigen
concentr
provid
basi
cell
dysfunct
result
upregul
program
cell
death
protein
checkpoint
molecul
hbvspecif
cell
line
interpret
intens
cell
respons
appear
invers
correl
hbv
dna
level
intens
hbvspecif
respons
detect
patient
lower
viral
load
bcell
respons
also
play
fundament
role
hbv
infect
antibodi
specif
hbsag
critic
neutral
free
extracellular
hbv
thu
prevent
viral
entri
suscept
hepatocyt
howev
antibodi
unabl
erad
intracellular
viru
task
fulfil
mhc
class
irestrict
virusspecif
cell
lytic
nonlyt
mechan
antihb
antibodi
also
produc
chronic
phase
infect
minim
amount
like
complex
larg
amount
hbv
envelop
protein
present
serum
antibodi
viral
nucleoprotein
antihbc
antihb
instead
persist
chronic
infect
detect
antihb
link
emerg
eminu
variant
find
undetect
hbv
dna
standard
assay
antihbc
absenc
hbsag
taken
surrog
evid
occult
hbv
infect
current
evid
support
view
coordin
activ
b
cell
critic
erad
infect
note
cell
control
cell
activ
antibodi
product
inabl
infect
host
mount
robust
virusspecif
antibodi
respons
correl
prematur
loss
cell
respons
establish
viral
persist
chimpanze
model
hbv
infect
interestingli
sera
contain
hightit
antihb
antibodi
provid
protect
upon
exposur
hbv
erad
close
relat
develop
neutral
antihb
antibodi
discoveri
sodium
taurochol
cotransport
polypeptid
ntcp
receptor
use
hbv
bind
infect
liver
cell
allow
identif
sequenc
use
hbv
bind
liver
cell
character
role
antibodi
inhibit
hbv
entri
infect
potenc
effici
antihepat
b
surfac
antibodi
control
hbv
also
come
earli
evid
show
hepat
b
vaccin
may
efficaci
even
given
exposur
administr
antihb
immunoglobulin
prevent
reinfect
liver
graft
humor
immun
seem
play
import
partial
understood
role
control
hbv
infect
also
exemplifi
observ
treatment
individu
manifest
occult
chronic
hbv
infect
specif
antib
cell
therapi
eg
monoclon
antibodi
rituximab
treat
autoimmun
diseas
nonhodgkin
lymphoma
may
carri
substanti
risk
hbv
reactiv
even
achiev
hbsag
clearanc
seroconvers
antihb
inde
rate
reactiv
rituximab
higher
similarli
match
patient
treat
cell
immunosuppress
agent
point
import
b
cell
respons
control
hbv
contrast
wealth
studi
antibodi
respons
hbv
protein
limit
inform
bcell
phenotyp
function
featur
hbv
infect
particularli
chronic
phase
note
contrast
evid
exhaust
cell
peripher
blood
patient
chronic
hbv
infect
bulk
peripher
blood
b
cell
express
sever
activ
marker
produc
larg
amount
immunoglobulin
respons
innat
adapt
immun
signal
significantli
b
cell
patient
chronic
hcv
infect
agreement
vigor
polyclon
bcell
activ
evid
upregul
bcell
exhaust
marker
ie
ad
support
concept
bulk
b
cell
popul
appar
remain
function
intact
set
would
explain
common
practic
patient
chronic
hbv
infect
maintain
abil
produc
antibodi
recal
antigen
abl
respond
solubl
protein
vaccin
howev
recent
evid
indic
enrich
hbsagspecif
b
cell
show
phenotyp
atyp
memori
b
cell
function
defect
subset
lack
express
result
chronic
pathogen
exposur
particularli
hiv
infect
b
cell
demonstr
alter
signal
home
differenti
antibodyproduc
cell
surviv
antiviralproinflammatori
cytokin
product
could
partial
rescu
blockad
find
suggest
persist
hbv
infect
drive
accumul
atyp
antigenspecif
b
cell
impair
antivir
capac
find
akin
simultan
publish
studi
suggest
b
cell
alter
limit
hbsagspecif
b
cell
affect
global
b
cell
popul
howev
last
find
would
appar
difficult
reconcil
previou
evid
conserv
global
bcell
function
chronic
hbv
infect
recent
interest
work
one
two
highli
reput
laboratori
shed
light
matter
inde
compar
character
b
cell
specif
hbv
nucleocapsid
envelop
protein
show
hbcagspecif
b
cell
prevail
hbsagspecif
patient
chronic
hbv
infect
abl
effici
differenti
immunoglobulinsecret
cell
compar
hbsagspecif
b
cell
moreov
hbcagspecif
b
cell
classic
phenotyp
transcriptom
profil
igg
memori
b
cell
wherea
hbsagspecif
b
cell
confirm
atyp
memori
b
cell
profil
one
first
report
dichotom
bcell
differenti
accord
antigen
specif
viral
infect
provid
plausibl
explan
higher
antihbc
titer
rel
low
antihb
titer
observ
sera
patient
chronic
hepat
b
recent
identifi
famili
regulatori
cell
regulatori
b
cell
breg
report
control
immun
respons
innat
adapt
level
studi
investig
role
breg
chronic
hepat
b
breg
classic
suppress
immun
function
secret
inhibitori
cytokin
inhibit
product
proinflammatori
cytokin
support
regulatori
cell
differenti
one
studi
report
increas
breg
cell
pbmc
patient
chronic
hbv
infect
spontan
hepat
flare
demonstr
suppress
mediat
activ
breg
hbvspecif
cell
vitro
enhanc
serum
level
inde
describ
chronic
hepat
b
particularli
socal
immun
activ
phase
howev
tempor
associ
necroinflammatori
flare
may
either
suggest
direct
breg
respons
via
suppress
hbvspecif
cell
therefor
diminish
viral
control
secondari
bregmedi
modul
inflammatori
flare
induc
virusspecif
cell
respons
switchoff
exagger
immun
activ
scenario
probabl
appli
chronic
infect
data
need
better
understand
role
breg
cell
clinic
set
human
memori
b
cell
plasma
cell
major
sourc
antibodi
inde
b
cell
undergo
somat
mutat
select
antigen
tcell
help
respons
pathogen
persist
life
memori
cell
given
individu
rapidli
respond
booster
immun
yield
larg
number
plasma
cell
even
though
longliv
plasma
cell
main
sourc
serum
antibodi
termin
differenti
cell
certainli
ideal
longterm
cultur
sever
method
develop
isol
human
monoclon
antibodi
humab
origin
rel
simpl
approach
consist
isol
singl
antigenspecif
epsteinbarr
viru
ebv
immort
b
cell
donor
hightit
specif
immunoglobulin
ig
laborintens
timeconsum
round
clone
step
approach
limit
instabl
cell
line
low
level
specif
antibodi
secret
poor
clone
effici
yield
low
number
agspecif
clone
usual
initi
seed
well
improv
origin
methodolog
repres
enrich
antigenspecif
b
cell
use
fluorochromeconjug
antigen
captur
b
cell
interest
thu
increas
chanc
obtain
specif
antigenspecif
bcell
clone
review
method
success
use
potenti
technic
issu
pertain
antigen
use
may
repres
unsurmount
hurdl
anoth
techniqu
extens
use
includ
phagedisplay
antibodi
librari
random
pair
antibodi
heavi
light
chain
enabl
use
appropri
target
antigen
screen
specif
antibodi
high
affin
antigen
human
transgen
mice
may
also
provid
altern
option
obtain
fulli
human
therapeut
antibodi
human
transgen
mice
endogen
murin
antibodi
gene
replac
human
ig
loci
transgen
mice
immun
ag
elicit
specif
human
antibodi
altern
approach
improv
clone
effici
origin
methodolog
consid
includ
select
memori
b
cell
ebv
immort
deliv
innat
immun
signal
agonist
cpg
oligodeoxynucleotid
potent
activ
memori
b
cell
ebvtransform
bcell
stabil
fusion
nonig
secret
mousehuman
myeloma
heterohybrid
use
approach
gener
number
humab
specif
hepat
c
viru
hcv
recent
hbv
among
hbvspecif
humab
develop
one
deriv
vaccin
individu
show
extrem
potent
neutral
activ
tupaia
belangeri
model
hbv
infect
vivo
wherea
other
appar
low
neutral
titer
interestingli
humab
show
highest
neutral
activ
recogn
conform
epitop
within
common
determin
major
envelop
protein
wherea
remaind
obtain
acut
hepat
b
convalesc
recogn
linear
epitop
envelop
polypeptid
data
entir
superimpos
obtain
ntcpexpress
cell
line
vivo
poorli
neutral
humab
instead
effici
neutral
ntcpexpress
cell
line
vitro
system
unpublish
data
antihbv
humab
origin
develop
obtain
sustain
reagent
immunoprophylaxi
hbv
reinfect
liver
transplant
recipi
set
treatment
accident
needlestick
prevent
verticalperinat
hbv
transmiss
antihb
antibodi
usual
administ
addit
prophylact
measur
wait
appear
neutral
antihb
antibodi
howev
escap
attent
anoth
potenti
import
applic
may
emerg
futur
adjuv
treatment
chronic
hbv
infect
antibodi
usual
effect
prophylaxi
given
shortli
viral
exposur
effici
declin
infect
howev
highli
potent
andor
broadli
crossreact
human
monoclon
antibodi
may
counteract
viral
escap
mechan
open
new
avenu
intervent
instanc
potent
envelopespecif
broadli
neutral
antibodi
superantibodi
identifi
may
potenti
therapeut
applic
chronic
hepat
b
potenti
advantag
antihb
humab
therapi
reli
possibl
regener
effect
cell
respons
patient
chronic
hbv
infect
whose
cell
dysfunct
result
exposur
larg
amount
hbv
envelop
protein
produc
excess
viral
replic
inde
remov
circul
hbsag
neutral
antihb
mab
report
rescu
exhaust
adapt
immun
respons
hepat
b
vaccin
eventu
lead
antihb
seroconvers
murin
model
may
thu
possibl
appli
concept
treatment
chronic
hepat
b
figur
notabl
murin
antihb
mab
employ
treat
hypogammaglobulinem
hbvinfect
individu
yield
reduc
hbv
dna
level
moreov
human
antihb
mab
alon
combin
use
patient
chronic
hbv
infect
result
substanti
decreas
hbsag
titer
interestingli
combin
therapi
success
clear
hbsag
therefor
combin
use
hbv
nucleo
ide
analog
definit
envisag
figur
import
emphas
potenti
danger
effect
immun
complex
format
follow
intraven
inject
monoclon
polyclon
antihb
antibodi
hbsag
posit
mice
chimpanze
human
subject
far
convincingli
demonstr
inde
renal
complic
immun
complex
diseas
describ
set
similarli
untoward
effect
report
hbvinfect
individu
receiv
high
dose
polyclon
hepat
b
immunoglobulin
anyway
import
principl
antihb
humab
administ
molar
excess
ensur
presenc
excess
uncomplex
humab
effect
neutral
elimin
circul
hbv
cooper
humor
cellular
arm
adapt
immun
requir
effici
elimin
pathogen
end
antivir
humab
exploit
mediat
antibodydepend
cellmedi
cytotox
adcc
take
place
via
specif
receptor
recogn
fc
fragment
igg
express
membran
sever
cell
involv
innat
adapt
immun
respons
famili
includ
sever
class
receptor
show
differ
affin
fc
fragment
one
low
affin
potent
activ
receptor
nk
cell
mediat
adcc
evalu
potenti
mediat
adcc
assay
develop
measur
abil
antivir
igg
trigger
activ
cell
express
receptor
obtain
interact
chimer
receptor
immun
complex
form
surfac
iggcoat
target
cell
result
activ
figur
combin
sequenti
treatment
chronic
hbv
infect
hbsagspecif
humab
nucleo
ide
analog
patient
chronic
hbv
infect
gray
treat
hbshumab
rescu
b
cell
exhaust
caus
hbv
envelop
protein
either
sequenti
combin
nucleo
ide
analog
nuc
reconstitut
hbvspecif
adapt
immun
would
ultim
increas
nuc
efficaci
result
viral
clearanc
green
teff
effector
cell
make
use
secret
mous
hybridoma
surrog
readout
thu
possibl
screen
differ
humab
potenti
effici
mediat
adcc
whether
adcc
play
role
set
hbv
infect
present
unclear
would
also
depend
abil
nk
cell
innat
lymphoid
cell
perform
function
well
affin
note
studi
use
mab
target
linear
epitop
aa
hbsag
first
loop
nterminu
locat
major
hydrophil
region
hbsag
promot
hbv
clearanc
blockad
viral
infect
even
interestingli
humab
target
ntcpbind
site
abl
reduc
hbv
dna
hbsag
level
murin
model
establish
hbv
infect
effici
mediat
adcc
abolish
antibodi
engin
fc
prevent
bind
find
discuss
suggest
humab
target
hbv
envelop
epitop
might
inde
potenti
combin
therapi
chronic
infect
individu
phase
clinic
trial
therefor
eagerli
await
set
mm
wrote
conceiv
manuscript
ac
dm
sm
contribut
concept
gener
data
bo
sv
sm
revis
manuscript
read
approv
submiss
public
part
project
entitl
curbsviluppo
di
nuov
molecol
candid
alla
cura
di
hbv
fund
region
lombardia
programma
operativo
regional
obiettivo
investimenti
favor
della
crescita
e
delloccupazion
cofinanziato
con
il
fesr
ass
prioritario
irafforzar
la
ricerca
lo
sviluppo
e
linnovazion
azion
all
collabor
di
r
per
lo
sviluppo
di
nuov
tecnologi
sostenibili
di
nuovi
prodotti
e
servizir
per
aggregazioni
call
per
lattivazion
di
un
percorso
sperimental
volto
alla
definizion
degli
accordi
per
la
ricerca
sviluppo
e
innovazion
art
della
legg
